Anaplastic large cell lymphoma

Summary

Anaplastic large cell lymphoma (MONDO:0020325) is a cancer (an umbrella term covering 5 Mondo subtypes) with 1 cohort gene (1 CIViC-evidence somatic driver) and 134 clinical trials. Molecularly, ALK Fusion confers sensitivity to Crizotinib in Anaplastic Large Cell Lymphoma (CIViC Level A); 9 further subtype–drug associations are mapped below. Top therapeutic interventions include romidepsin, brentuximab vedotin, and cytarabine.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Umbrella term: 5 Mondo subtypes
• Cohort genes: 1
• Clinical trials: 134
• Precision-medicine evidence (CIViC): 10 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000	2	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	anaplastic large cell lymphoma
Mondo ID	MONDO:0020325
EFO	EFO:0003032
MeSH	D017728
Orphanet	98841
DOID	DOID:0050744
NCIT	C3720
SNOMED CT	277637000
UMLS	C0206180
MedGen	61533
GARD	0003112
Is cancer (heuristic)	yes

Also known as: ALCL · anaplastic large cell lymphoma · CD30 Positive anaplastic large cell lymphoma · CD30 positive anaplastic large cell lymphoma · Ki-1 lymphoma · Ki-1 positive anaplastic large cell lymphoma · Ki-1+ ALCL · Ki-1+ anaplastic large cell lymphoma · primary systemic ALCL · sACL

Data availability: 7 cell lines.

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells › mature T-cell and NK-cell non-Hodgkin lymphoma › anaplastic large cell lymphoma

Related subtypes (7): angioimmunoblastic T-cell lymphoma, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, hydroa vacciniforme-like lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocyte leukemia, aggressive NK-cell leukemia, breast implant-associated anaplastic large cell lymphoma

Subtypes (5): central nervous system anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, ALK-negative anaplastic large cell lymphoma, small cell variant anaplastic large cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
ALK	Act	BRCA,HCC,NBL,NSCLC,PROSTATE,SCLC	CIViC #1

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ALK	Orphanet:146	Differentiated thyroid carcinoma
ALK	Orphanet:178342	Inflammatory myofibroblastic tumor
ALK	Orphanet:251877	Ganglioneuroblastoma
ALK	Orphanet:251992	Ganglioneuroma
ALK	Orphanet:300895	ALK-positive anaplastic large cell lymphoma
ALK	Orphanet:364043	ALK-positive large B-cell lymphoma
ALK	Orphanet:626	Large/giant congenital melanocytic nevus
ALK	Orphanet:635	Neuroblastoma

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ALK	HGNC:427	ENSG00000171094	Q9UM73	ALK tyrosine kinase receptor	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ALK	ALK tyrosine kinase receptor	Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ALK	Kinase	yes	2.7.10.1	Prot_kinase_dom, MAM_dom, Ser-Thr/Tyr_kinase_cat_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ cell	1
male germ line stem cell (sensu Vertebrata) in testis	1
sperm	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ALK	181	broad	marker	sperm, male germ cell, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ALK	4,792

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ALK	Q9UM73	79

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 17. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Drug resistance of ALK mutants	1	11420.0×	2e-04	ALK
ASP-3026-resistant ALK mutants	1	11420.0×	2e-04	ALK
NVP-TAE684-resistant ALK mutants	1	11420.0×	2e-04	ALK
alectinib-resistant ALK mutants	1	11420.0×	2e-04	ALK
brigatinib-resistant ALK mutants	1	11420.0×	2e-04	ALK
ceritinib-resistant ALK mutants	1	11420.0×	2e-04	ALK
crizotinib-resistant ALK mutants	1	11420.0×	2e-04	ALK
lorlatinib-resistant ALK mutants	1	11420.0×	2e-04	ALK
MDK and PTN in ALK signaling	1	2855.0×	7e-04	ALK
ALK mutants bind TKIs	1	951.7×	0.002	ALK
Signaling by ALK	1	571.0×	0.003	ALK
Signaling by ALK in cancer	1	271.9×	0.005	ALK
Signaling by ALK fusions and activated point mutants	1	150.3×	0.009	ALK
Diseases of signal transduction by growth factor receptors and second messengers	1	56.8×	0.021	ALK
Signaling by Receptor Tyrosine Kinases	1	51.7×	0.022	ALK
Disease	1	13.1×	0.081	ALK
Signal Transduction	1	10.2×	0.098	ALK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
response to environmental enrichment	1	8426.0×	0.002	ALK
regulation of dopamine receptor signaling pathway	1	4213.0×	0.002	ALK
swimming behavior	1	3370.4×	0.002	ALK
response to stress	1	2407.4×	0.002	ALK
peptidyl-tyrosine autophosphorylation	1	1872.4×	0.002	ALK
phosphorylation	1	1296.3×	0.002	ALK
positive regulation of dendrite development	1	991.3×	0.003	ALK
negative regulation of lipid catabolic process	1	842.6×	0.003	ALK
regulation of neuron differentiation	1	732.7×	0.003	ALK
adult behavior	1	468.1×	0.004	ALK
energy homeostasis	1	271.8×	0.006	ALK
neuron development	1	255.3×	0.006	ALK
hippocampus development	1	230.8×	0.006	ALK
obsolete positive regulation of NF-kappaB transcription factor activity	1	205.5×	0.007	ALK
cell surface receptor protein tyrosine kinase signaling pathway	1	173.7×	0.007	ALK
protein autophosphorylation	1	145.3×	0.008	ALK
regulation of cell population proliferation	1	115.4×	0.010	ALK
regulation of apoptotic process	1	83.4×	0.013	ALK
signal transduction	1	16.1×	0.062	ALK

Therapeutics

Drugs indicated for this disease

1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Brentuximab Vedotin	Approved (phase 4)
Bexarotene	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alectinib, Belinostat, Brigatinib, Ceritinib, Cisplatin, Crizotinib, Cytarabine, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Fludarabine Phosphate, Gemcitabine, Ifosfamide, Ixabepilone, Lorlatinib, Melphalan, Methylprednisolone, Mycophenolate Mofetil, Nivolumab, Prednisolone, Prednisone, Rasburicase, Rituximab, Romidepsin, SGN-30, TOSITUMOMAB 131I, Tacrolimus Anhydrous, Tanespimycin, Venetoclax, Vincristine, Vinorelbine, YTTRIUM Y 90 IBRITUMOMAB TIUXETAN.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ALK	CERITINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ALK	61	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CERITINIB	4	ALK
BOSUTINIB	4	ALK
CRIZOTINIB	4	ALK
ALECTINIB	4	ALK
ENTRECTINIB	4	ALK
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK
RUXOLITINIB	4	ALK
INFIGRATINIB PHOSPHATE	4	ALK
INFIGRATINIB	4	ALK
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK
NINTEDANIB	4	ALK
SUNITINIB	4	ALK
ERLOTINIB	4	ALK
MIDOSTAURIN	4	ALK
DACTOLISIB	3	ALK
LINIFANIB	3	ALK
SEMAXANIB	3	ALK
CANERTINIB	3	ALK
ROCILETINIB	3	ALK
ALVOCIDIB	3	ALK
CEDIRANIB	3	ALK
QUERCETIN	3	ALK

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ALK	1,815	Binding:1801, Functional:13, ADMET:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ALK	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ALK	1,815

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

27 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
BOSUTINIB	4	ALK
ENTRECTINIB	4	ALK
LORLATINIB	4	ALK
GILTERITINIB	4	ALK
OSIMERTINIB	4	ALK
BRIGATINIB	4	ALK
REPOTRECTINIB	4	ALK
FEDRATINIB	4	ALK
RUXOLITINIB	4	ALK
INFIGRATINIB PHOSPHATE	4	ALK
INFIGRATINIB	4	ALK
PALBOCICLIB	4	ALK
VANDETANIB	4	ALK
UPADACITINIB	4	ALK
PAZOPANIB	4	ALK
NINTEDANIB	4	ALK
SUNITINIB	4	ALK
ERLOTINIB	4	ALK
MIDOSTAURIN	4	ALK
DACTOLISIB	3	ALK
LINIFANIB	3	ALK
SEMAXANIB	3	ALK
CANERTINIB	3	ALK
ROCILETINIB	3	ALK
ALVOCIDIB	3	ALK
CEDIRANIB	3	ALK
QUERCETIN	3	ALK

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ALK
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 134.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	50
PHASE2	45
PHASE1/PHASE2	18
Not specified	14
EARLY_PHASE1	3
PHASE2/PHASE3	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05160922	PHASE4	ACTIVE_NOT_RECRUITING	Crizotinib Continuation Clinical Study
NCT05770037	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT01777152	PHASE3	COMPLETED	ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
NCT04021082	PHASE2/PHASE3	WITHDRAWN	CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
NCT02978625	PHASE2	ACTIVE_NOT_RECRUITING	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT03278782	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT03598998	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT04195633	PHASE2	RECRUITING	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
NCT06137144	PHASE1/PHASE2	RECRUITING	AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT07535762	PHASE2	NOT_YET_RECRUITING	Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT00001337	PHASE2	COMPLETED	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
NCT00005080	PHASE2	COMPLETED	506U78 in Treating Patients With Lymphoma
NCT00006251	PHASE1/PHASE2	COMPLETED	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
NCT00016094	PHASE2	COMPLETED	S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma
NCT00040846	PHASE2	COMPLETED	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
NCT00049504	PHASE2	COMPLETED	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
NCT00058019	PHASE2	COMPLETED	Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
NCT00072514	PHASE2	COMPLETED	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
NCT00073918	PHASE2	COMPLETED	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00078858	PHASE1/PHASE2	COMPLETED	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
NCT00079755	PHASE2	COMPLETED	Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
NCT00082888	PHASE2	COMPLETED	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00089011	PHASE2	COMPLETED	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
NCT00112723	PHASE1/PHASE2	TERMINATED	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
NCT00117988	PHASE2	COMPLETED	17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma
NCT00118352	PHASE2	COMPLETED	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00131937	PHASE2	COMPLETED	Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma
NCT00278382	PHASE2	COMPLETED	Sorafenib in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma
NCT00310128	PHASE2	WITHDRAWN	Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin’s Lymphoma
NCT00354107	PHASE1/PHASE2	TERMINATED	Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
NCT00365274	PHASE2	TERMINATED	SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
NCT00601718	PHASE1/PHASE2	COMPLETED	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00644189	PHASE1/PHASE2	COMPLETED	Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
NCT00801918	PHASE2	WITHDRAWN	Denileukine Diftitox for Relapsed ALCL
NCT00901147	PHASE2	COMPLETED	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma
NCT00918333	PHASE1/PHASE2	COMPLETED	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
NCT00939770	PHASE1/PHASE2	COMPLETED	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
NCT01028716	PHASE2	TERMINATED	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01035463	PHASE1/PHASE2	COMPLETED	Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
NCT01075321	PHASE1/PHASE2	COMPLETED	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROMIDEPSIN	4	5
BRENTUXIMAB VEDOTIN	4	4
CYTARABINE	4	4
BELINOSTAT	4	3
BENDAMUSTINE HYDROCHLORIDE	4	3
PANOBINOSTAT	4	3
PROCHLORPERAZINE	4	3
ALECTINIB	4	2
ALEMTUZUMAB	4	2
CRIZOTINIB	4	2
IMATINIB	4	2
PRALATREXATE	4	2
SORAFENIB TOSYLATE	4	2
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	4	2
CERITINIB	4	1
CLOFARABINE	4	1
DEFERASIROX	4	1
DENILEUKIN DIFTITOX	4	1
DOCUSATE	4	1
DUVELISIB	4	1
FOSCARNET	4	1
FOSCARNET SODIUM	4	1
GANCICLOVIR	4	1
ISOTRETINOIN	4	1
IXABEPILONE	4	1
LACTULOSE	4	1
MYCOPHENOLATE SODIUM	4	1
NELARABINE	4	1
OMEPRAZOLE	4	1
TALIMOGENE LAHERPAREPVEC	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 10 predictive associations from 15 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
ALK Fusion	Crizotinib	Sensitivity/Response	CIViC A	EID11218 +4
NPM1::ALK Fusion	Crizotinib	Sensitivity/Response	CIViC B	EID1241 +1
ALK Fusion	Ceritinib	Sensitivity/Response	CIViC C	EID7546
ALK F1174L AND NPM1::ALK Fusion	Ceritinib	Resistance	CIViC D	EID12658
ALK G1269A AND NPM1::ALK Fusion	Crizotinib	Resistance	CIViC D	EID12654
ALK I1171	Crizotinib	Resistance	CIViC D	EID4612
ALK L1196Q	Crizotinib	Resistance	CIViC D	EID4609
NPM1::ALK Fusion AND ALK I1171N	Crizotinib	Resistance	CIViC D	EID4632
NPM1::ALK Fusion AND ALK I1171S	Crizotinib	Resistance	CIViC D	EID12653
NPM1::ALK Fusion AND ALK T1151M	Ceritinib	Resistance	CIViC D	EID12659